Your browser doesn't support javascript.
loading
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft, Tara; Aktas, Bilge; Schroeder, Brock; Bossuyt, Veerle; DiGiovanna, Michael; Abu-Khalaf, Maysa; Chung, Gina; Silber, Andrea; Hofstatter, Erin; Mougalian, Sarah; Epstein, Lianne; Hatzis, Christos; Schnabel, Cathy; Pusztai, Lajos.
Affiliation
  • Sanft T; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. tara.sanft@yale.edu.
  • Aktas B; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. bilge.aktas@yale.edu.
  • Schroeder B; BioTheranostics, Inc., 9640 Towne Centre Drive, Suite 200, San Diego, CA, 92121, USA. brock.schroeder@biotheranostics.com.
  • Bossuyt V; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. veerle.bossuyt@yale.edu.
  • DiGiovanna M; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. michaeal.digiovanna@yale.edu.
  • Abu-Khalaf M; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. maysa.abu-khalaf@yale.edu.
  • Chung G; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. gina.chung@yale.edu.
  • Silber A; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. andrea.silber@yale.edu.
  • Hofstatter E; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. erin.hofstatter@yale.edu.
  • Mougalian S; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. sarah.mougalian@yale.edu.
  • Epstein L; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. lianne.epstein@yale.edu.
  • Hatzis C; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. christos.hatzis@yale.edu.
  • Schnabel C; BioTheranostics, Inc., 9640 Towne Centre Drive, Suite 200, San Diego, CA, 92121, USA. cathy.schnabel@biotheranostics.com.
  • Pusztai L; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, PO Box 208032, 333 Cedar St, New Haven, CT, 06520-8032, USA. lajos.pusztai@yale.edu.
Breast Cancer Res Treat ; 154(3): 533-41, 2015 Dec.
Article in En | MEDLINE | ID: mdl-26578401
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Decision Making Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2015 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Decision Making Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2015 Type: Article Affiliation country: United States